Bayer Invests $2.2 Billion in New Ohio Manufacturing Site

New Albany, Ohio, Oct. 02, 2026 /CourierPR/ -- Bayer, a global enterprise with core competencies in the life science fields of health care and nutrition, has announced a significant expansion in the United States. The company plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio. This investment is expected to create around 600 high-value jobs in the New Albany International Business Park and roughly 1,500 construction jobs during the facility’s construction.

Building on more than $7 billion in U.S. pharma R&D and manufacturing spending over the past five years, the project is a central element of Bayer’s long-term growth strategy and commitment to innovation and patient access in its largest pharmaceuticals market.

The flexible, modular campus will be designed to combine drug substance and drug product manufacturing, leverage advanced digital and automation technologies, and support Bayer’s growing portfolio in oncology, cardiovascular, and renal care. The first module, dedicated to drug substance manufacturing, is expected to become operational in 2031. A second module for drug product manufacturing is planned to follow in 2034.

Workforce readiness was central to Ohio's appeal. Bayer will draw on the Ohio Life Science Training Center, under construction and scheduled to open in summer 2027, to train Ohioans to work as biomanufacturing operators and technicians. JobsOhio is investing up to $30 million in the center, alongside nearly $8 million from the City of New Albany, the State of Ohio, and The New Albany Company, as part of a strategy that makes life sciences an economic development priority for the state.

Ohio’s commitment to innovation and infrastructure has made it a top destination for businesses. CNBC named Ohio the No. 1 state for business in 2026, citing best-in-class infrastructure and shovel-ready sites. Two decades of master planning in New Albany to ensure access to power, water, and infrastructure allow projects like this to move quickly. Bayer joins a growing life sciences cluster in the New Albany International Business Park that includes Amgen, Hims & Hers, American Regent, and Pharmavite.

These companies benefit from operating inside the Ohio Discovery Corridor, which connects nine world-class medical and research facilities and leading academic institutions. This network provides access to 39,000 annual STEM graduates, a $1 billion annual NIH-funded research engine, and collaborative partnerships that drive ground-breaking research and innovation.

In fiscal 2025, Bayer employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. The new facility will form part of a new U.S.-based collaboration ecosystem, connecting cutting-edge academic innovation with advanced manufacturing expertise to create a strong ecosystem that supports future-ready pharmaceutical production.

The Bayer project will pursue a Job Creation Tax Credit from the Ohio Department of Development at a future Tax Credit Authority meeting. The company also plans to pursue JobsOhio assistance for the project, which would be made public after a final agreement is executed.